nach oben

ADHD Attention Deficit and Hyperactivity Disorders

Erschienen in:

01.06.2012 | Original Article

Heart rate variability and methylphenidate in children with ADHD

verfasst von: Reiner Buchhorn, Annette Conzelmann, Christian Willaschek, Dagmar Störk, Regina Taurines, Tobias J. Renner

Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Although an extensive number of studies support the efficacy and tolerability of stimulants in the treatment of attention deficit/hyperactivity disorder (ADHD), in recent years, increasing concerns have been raised about their cardiovascular safety. We investigated whether a time domain analysis of heart rate variability (HRV) recordings in 24-h ECG under medication with stimulants yielded new information about therapy control in ADHD. We analysed the HRV parameter standard deviation of all normal sinus RR intervals over 24 h (SDNN), percentage of successive normal sinus RR intervals > 50 ms (pNN50) and root-mean-square of the successive normal sinus RR interval difference (rMSSD) from 23 children diagnosed by ADHD (19 boys and 4 girls), aged 10.5 ± 2.2 years, who were consecutively referred to our outpatient clinic for paediatric cardiology. Eleven children received medication with methylphenidate (MPH), while twelve children were initially examined without medication. Of these, eight probands were re-examined after therapy with MPH was established. Controls comprised 19 children (10 boys, 9 girls) from our Holter ECG data base without any cardiac or circulatory disease. Compared to healthy controls, the ADHD children with and without MPH treatment showed significantly higher mean heart rates (ADHD without MPH: 94.3 ± 2.2; ADHD with MPH: 90.5 ± 1.8, controls: 84.7 ± 1.8). pNN50 (ADHD without MPH: 6.5 ± 2.7; ADHD with MPH: 14.2 ± 6.9, controls: 21.5 ± 9.0) and rMSSD (ADHD without MPH: 26.1 ± 4.1; ADHD with MPH: 36.7 ± 8.3, controls: 44.5 ± 10.1) were lowest in ADHD children without MPH, middle in ADHD children with MPH and highest in controls. SDNN values were not significantly different. The hourly analysis shows highly significant reduced pNN50 and rMSSD values in untreated ADHD children between 5:00 pm and 6:00 am while the pattern approaches to levels of controls during MPH treatment. Data of this pilot study indicate a decreased vagal tone with significantly diminished HRV and higher heart rates in unmedicated ADHD children. These parameters of autonomic activation are ameliorated by MPH treatment. No evidence for negative impact of MPH on HRV was detected. Further studies will clarify a potential cardio-protective effect of MPH in ADHD.

Al Haddad H, Laursen PB, Ahmaidi S, Buchheit M (2009) Nocturnal heart rate variability following supramaximal intermittent exercise. Int J Sports Physiol Perform 4:435–447PubMed

Arnsten AF (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23(Suppl 1):33–41PubMedCrossRef

Buchhorn R, Hulpke-Wette M, Nothroff J, Paul T (2002) Heart rate variability in infants with heart failure due to congenital heart disease: reversal of depressed heart rate variability by propranolol. Med Sci Monit 8:CR661-6PubMed

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904PubMedCrossRef

Denchev P, Kaltman JR, Schoenbaum M, Vitiello B (2010) Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 121:1329–1337PubMedCrossRef

Faraone SV (2009) Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T 34:678–694PubMed

Fei L, Anderson MH, Katritsis D, Sneddon J, Statters DJ, Malik M, Camm AJ (1994) Decreased heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease. Br Heart J 71:16–21PubMedCrossRef

Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001PubMedCrossRef

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (2011) ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 306:2673–2683PubMedCrossRef

Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J (2009) Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 155:84–89PubMedCrossRef

Huang YS, Tsai MH (2011) Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder Current Status of Knowledge. Cns Drugs 25:539–554PubMedCrossRef

Imeraj L, Antrop I, Roeyers H, Deschepper E, Bal S, Deboutte D (2011) Diurnal variations in arousal: a naturalistic heart rate study in children with ADHD. Eur Child Adolesc Psychiatry 20:381–392PubMedCrossRef

Jacob CP, Romanos J, Dempfle A, Heine M, Windemuth-Kieselbach C, Kruse A, Reif A, Walitza S, Romanos M, Strobel A, Brocke B, Schäfer H, Schmidtke A, Böning J, Lesch K (2007) Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci 257:309–317PubMedCrossRef

Leslie LK, Alexander ME, Trikalinos TA, Cohen JT, Parsons SK, Newburger JW (2008) Reexamining the emperor’s new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. Circ Cardiovasc Qual Outcomes 1:134–137PubMedCrossRef

McCarthy S, Cranswick N, Potts L, Taylor E, Wong ICK (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 32:1089–1096PubMedCrossRef

Negrao BL, Bipath P, van der Westhuizen D, Viljoen M (2011) Autonomic correlates at rest and during evoked attention in children with attention-deficit/hyperactivity disorder and effects of methylphenidate. Neuropsychobiology 63:82–91PubMedCrossRef

Polanczyk G, Rohde LA (2007) Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 20:386–392PubMedCrossRef

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948PubMedCrossRef

Polderman TJ, Boomsma DI, Bartels M, Verhulst FC, Huizink AC (2010) A systematic review of prospective studies on attention problems and academic achievement. Acta Psychiatr Scand 122:271–284PubMedCrossRef

Renner T, Gerlach M, Romanos M, Herrmann M, Reif A, Fallgatter A, Lesch K (2008) Neurobiologie des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms. Nervenarzt 79:771–781PubMedCrossRef

Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S (2011) Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents. Pediatrics 127:1102–1110PubMedCrossRef

Schlander M, Trott GE, Schwarz O (2010) The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness. Nervenarzt 81:289–300PubMedCrossRef

Schubert I, Köster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int 107:615–621PubMed

Singh RB, Weydahl A, Otsuka K, Watanabe Y, Yano S, Mori H, Ichimaru Y, Mitsutake G, Sato Y, Fanghong L, Zhao ZY, Kartik C, Gvozdjakova A (2001) Can nutrition influence circadian rhythm and heart rate variability? Biomed Pharmacother 55(Suppl 1):115s–124sPubMed

Singh RB, Kartik C, Otsuka K, Pella D, Pella J (2002) Brain-heart connection and the risk of heart attack. Biomed Pharmacother 56(Suppl 2):257s–265sPubMed

Task Force of the European Society of Cardiology and the North American society of Pacing (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 17:354–381CrossRef

Taurines R, Schmitt J, Renner T, Conner AC, Warnke A, Romanos M (2010) Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord 2:267–289PubMedCrossRef

Tonhajzerova I, Ondrejka I, Adamik P, Hruby R, Javorka M, Trunkvalterova Z, Mokra D, Javorka K (2009) Changes in the cardiac autonomic regulation in children with attention deficit hyperactivity disorder (ADHD). Indian J Med Res 130:44–50PubMed

Vaseghi M, Shivkumar K (2008) The role of the autonomic nervous system in sudden cardiac death. Prog Cardiovasc Dis 50:404–419PubMedCrossRef

Titel: Heart rate variability and methylphenidate in children with ADHD
verfasst von: Reiner Buchhorn
Annette Conzelmann
Christian Willaschek
Dagmar Störk
Regina Taurines
Tobias J. Renner
Publikationsdatum: 01.06.2012
Verlag: Springer Vienna
Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders / Ausgabe 2/2012
Print ISSN: 1866-6116
Elektronische ISSN: 1866-6647
DOI: https://doi.org/10.1007/s12402-012-0072-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood

Cortisol responses in children and adults with attention deficit hyperactivity disorder (ADHD): a possible marker of inhibition deficits

ADHD in adults: a concept in evolution

The effects of the neurotoxin DSP4 on spatial learning and memory in Wistar rats